RI FISHER, CA COLTMAN Jr, JH … - Annals of internal …, 1988 - Am Coll Physicians RICHARD I. FISHER, MD; CHARLES A. COLTMAN, Jr., MD; JAMES H. DOROSHOW, MD; ANTHONY A. RAYNER, MD;
MICHAEL J. HAWKINS, MD; JAMES W. MIER, MD; PETER WIERNIK, MD; JOHN D. MCMANNIS, Ph.D.; GEOFFREY R.
WEISS, MD; KIM A. MARGOLIN, MD; ... Cited by 265 - Related articles - All 4 versions
- ►jcojournal.org [PDF] DR Parkinson, RI Fisher, AA Rayner, E Paietta, … - Journal of Clinical …, 1990 - jcojournal.org T HE USE OF high-dose interleukin-2 (IL-2) together with LAK cells results in reproduc- ible tumor
responses in patients with metastatic or unresectable renal cell carcinoma.-3 Since the toxicity of
this therapy is largely related to ... Cited by 66 - Related articles - All 5 versions
- ►ascopubs.org [PDF] JP Dutcher, S Creekmore, GR Weiss, K … - Journal of Clinical …, 1989 - jco.ascopubs.org The mononuclear cell population was then expanded in vitro and demonstrated cytotoxic activity. The
activated autologous cells were subsequently reinfused into the patients with additional IL-2.7
Responses were noted at the higher ... Cited by 173 - Related articles - All 5 versions
- ►jcojournal.org [PDF] GR Weiss, KA Margolin, FR Aronson, M Sznol, … - Journal of Clinical …, 1992 - jcojournal.org T HE INTRODUCTION of adoptive immunotherapy for the treatment of patients with advanced renal cell
carcinoma was accompanied by both optimism for the promise of this new form of cancer treatment and ... From the Extramural IL-2/LAK ... Cited by 114 - Related articles - All 6 versions
WH West, KW Tauer, JR Yannelli, GD … - New England Journal …, 1987 - content.nejm.org Adoptive immunotherapy involving bolus-dose recombinant interleukin-2 (rIL-2) has been reported to
induce tumor regression in some patients with cancer, but has been associated with severe fluid
retention and cardiopulmonary ... Cited by 854 - Related articles - All 3 versions
- ►oxfordjournals.org [PDF] JA Sosman, PC Kohler, J Hank, KH Moore … - JNCI Journal of the …, 1988 - jnci.oxfordjournals.org 5. FOGH J, FOGH JM, ORFEO T. One hundred and twenty-seven cultured human tumor cell lines producing
tumors in nude mice. J Natl Cancer Inst 1977;59:221-226. 6. MCCULLOUGH J, NEWBURGER A, GANDERUP G.
Melanoma: athymic nude mouse model. ... Cited by 110 - Related articles - All 6 versions
- ►oxfordjournals.org [PDF] RM Bukowski, P Goodman, ED Crawford, … - JNCI Journal of the …, 1990 - jnci.oxfordjournals.org A phase II trial of intermittent high- dose recombinant interleukin-2 (rlL- 2) was initiated to
evaluate the re- sponse rate, remission duration, and toxic effects in patients with measur- able
metastatic renal cell carcinoma. ... Cited by 64 - Related articles - All 5 versions
SA Rosenberg, MT Lotze, LM Muul, AE … - New England Journal …, 1987 - content.nejm.org We studied the effects of adoptive immunotherapy with lymphokine-activated killer (LAK) cells plus
interleukin-2 or therapy with high-dose interleukin-2 alone in 157 patients with metastatic cancer
for whom standard therapy had ... Cited by 1742 - Related articles - All 3 versions
- ►ascopubs.org [PDF] KA Margolin, AA Rayner, MJ Hawkins, MB … - Journal of Clinical …, 1989 - jco.ascopubs.org From the City of Hope Cancer Research Center, Duarte, CA; University of California at San Francisco;
Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD; Tufts-New England
Medical Center, Boston; Albert ... Cited by 225 - Related articles - All 6 versions
- ►ascopubs.org [PDF] MB Atkins, J Sparano, RI Fisher, GR Weiss, … - Journal of Clinical …, 1993 - jco.ascopubs.org Purpose: To determine better the activity of high- dose interleukin-2 (IL-2) either alone or in
combination with interferon alfa-2b (IFN; Schering-Plough, Kenil- worth, NJ) in patients with
metastatic renal cell carci- noma, ... Cited by 135 - Related articles - BL Direct - All 6 versions
